The Effect of Probiotics ATG-F4 in Cancer Patients

Launched by CHUNGNAM NATIONAL UNIVERSITY HOSPITAL · May 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a specific type of probiotics, called ATG-F4, in patients with advanced pancreatic or colorectal cancer who are receiving a chemotherapy treatment that includes oxaliplatin. The goal is to see if these probiotics can help reduce side effects from the treatment and improve the patients' overall well-being. If you're 19 years or older, have been diagnosed with either of these cancers, and are currently undergoing oxaliplatin-based chemotherapy, you may be eligible to participate.

Participants in the trial will take the probiotics for up to 12 weeks and will be asked to fill out questionnaires about their health and side effects during this period. They will also provide blood and stool samples for further analysis. It's important to note that patients with certain conditions, such as severe infections or those who have recently taken antibiotics or probiotics, may not be able to join the study. Overall, this trial aims to learn more about how probiotics can support cancer patients during their treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with advanced colorectal cancer or pancreatic cancer who are undergoing treatment with Oxaliplatin-based chemotherapy at Chungnam National University Hospital, including both newly diagnosed and recurrent cases.
• • Aged 19 years or older.
• • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 points.
• • Expected life expectancy of at least 3 months.
• • Ability to understand the requirements of the clinical trial and willingness to sign the informed consent form.
• Exclusion Criteria:
• • Presence of known brain metastases.
• • Malignant bowel obstruction requiring surgical intervention.
• • Uncontrolled, active infections, symptomatic congestive heart failure, unstable angina, cardiac arrhythmias, or any psychiatric/social conditions that may limit compliance with the study requirements.
• • Partial or complete intestinal obstruction.
• • Pregnant or lactating women.
• • Use of antibiotics, antifungals, or antiviral agents on more than one occasion within the past month.
• • Consumption of probiotics products or fermented milk more than twice within the past month.
• • Patients with neurological or psychiatric disorders.

Trial Officials